The life sciences industry is at an inflection point. By 2030, one in six people globally will be aged 60 years or over, and the population aged 80 and older is expected to triple by 2050. For life science leaders, this demographic transformation is not merely a healthcare challenge to manage; it represents one of the most significant strategic opportunities of the next decade. Companies that understand longevity as a core growth thesis, rather than a narrow geriatrics niche, will capture disproportionate value and shape the future of the industry.[1][2]

Longevity is shifting from simply adding years of life to extending "healthspan," the period of life spent in good health with functional independence. We are beginning to see a paradigm shift from disease-focused treatments to those that address the underlying mechanisms of aging, biological systems, and wellness. This distinction matters enormously for strategy. Companies that design around functional outcomes rather than age alone will find:

The longevity economy, defined by the rising economic and social participation of people aged 50 and above, contributed $45 trillion to global GDP in 2020, representing approximately 34% of total GDP. This figure is growing, especially as older adults become a key force in consumer and healthcare markets. The global anti-aging market, valued at approximately $85 billion in 2025, is expected to surpass $120 billion by 2030. For life science organizations, the strategic imperative is clear: longevity is not a specialty segment but a lens through which portfolio, evidence, and commercial strategies must be evaluated.[3][4]

The numbers are striking. By 2030, the share of the global population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double to 2.1 billion, and persons aged 80 years or older will triple to reach 426 million.[1]

In the United States, the shift is equally pronounced. By 2030, one in five people, or more than 20% of the population, will be over 65 years of age, amounting to approximately 71 million older Americans. The number of Americans ages 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050. By 2040, the 85 and older population is projected to more than double, from 6.5 million in 2022 to 13.7 million. Older adults in 2022 already represented 17% of the U.S. population, and by 2040 they are projected to comprise 22%.[5][6][7]

These projections are not hypothetical. All baby boomers will be age 65 or older by 2030, representing the largest such cohort in U.S. history. For life science companies, this means the patient populations, clinical trial participants, and end users of therapeutics and devices will increasingly be older adults with complex, multi-morbid profiles.[8]

The aging trajectory creates pressure at every level of the healthcare system. Common conditions in older age include hearing loss, cataracts, back and neck pain, osteoarthritis, chronic obstructive pulmonary disease, diabetes, depression, and dementia. As people age, they are more likely to experience several conditions at the same time, a reality that complicates treatment regimens, increases polypharmacy risks, and creates fragmented care journeys.[1]

The healthcare workforce faces acute strain. About 70 percent of American adults aged 65 and older will need some form of long-term care in the future. Yet the caregiver shortage is severe, with approximately 718,900 openings for home health and personal care aides projected each year over the next decade. Seventeen percent of Americans provide unpaid care to adults over the age of 50, spending on average 23.7 hours a week managing care. Despite caregivers' crucial role in managing their loved ones' health, federal and state support for unpaid caregivers remains inadequate, leading to mental health struggles, physical exhaustion, and financial insecurity.[9][10]

Older Americans face a growing caregiving gap, especially those with lower incomes and dementia. Demand for elder care is expected to increase sharply with a rise in the number of Americans living with Alzheimer's disease, which could more than double by 2050 to 13 million, from 6 million today. These system-wide pressures directly affect life science companies: pricing scrutiny intensifies, evidence requirements become more demanding, and the need for holistic solutions that go beyond the pill grows.[6]

Patient centricity for older adults requires a fundamental rethinking of how therapies, services, and digital tools are conceived and delivered. Evidence suggests that the proportion of life in good health has remained broadly constant, implying that additional years are often in poor health. If added years are dominated by declines in physical and mental capacity, the implications for older people and for society are more negative.[1]

True patient centricity in the longevity era means designing around function, autonomy, and burden of treatment, not just satisfaction scores. This includes regimen complexity, caregiver impact, and digital usability. From a pharma perspective, patient centricity is about focusing as much on the patient journey and overall quality of life as it is on making sure patients can access treatments that address their symptoms. This shift will require a dynamic flow of data and information to empower patients and their caregivers to make informed decisions about their care.[11][1]

Addressing the unmet care and technical support needs of an aging population and designing services and solutions around the needs or desires of older adults is becoming an urgent public health priority. For life science companies, this means integrating patient input into clinical trial design, developing simplified regimens, and ensuring digital support tools are accessible and usable for older populations.[12]

A critical shift is underway in how evidence is generated and used for older populations. Wearable devices offer real-time monitoring of physiological parameters such as heart rate, blood pressure, step count, and sleep quality, providing data support for disease warning and health management. Research on wearable devices for the elderly has grown rapidly, with an annual publication growth rate of 7.65% from 2014 to 2024, reflecting global attention to these capabilities.[12]

The integration of smart wearable devices with intelligent healthcare technologies contributes to improving the accessibility and efficiency of medical services, enabling data-driven precision health management and optimizing health service models for the elderly. Fall risk assessment and prevention remain critical challenges in elderly health management, with wearable devices achieving accuracy comparable to traditional manual assessment while reducing human error.[12]

Importantly, future cohorts of older adults will be more digitally literate than stereotypes suggest. Education levels among older Americans are increasing; among people ages 65 and older in 1965, only 5% had completed four years of college or more, and by 2023, this share had risen to 33%. This rising digital literacy, combined with technology adoption, creates continuous real-world data streams that life science companies can leverage.[6]

The FDA has a long history of using real-world data and real-world evidence to monitor and evaluate the postmarket safety of approved drugs. RWE has also been used historically to support effectiveness, and advances in the availability and analysis of RWD have increased the potential for generating robust RWE to support FDA regulatory decisions. Recent FDA regulatory approvals have utilized RWD from sources including medical records, registries, and claims data for confirmatory evidence and even pivotal studies. For older, multi-morbid populations where traditional randomized controlled trials are difficult to conduct, RWE becomes an essential tool for demonstrating real-world value.[13]

The care ecosystem for older adults is transforming from hospital-centric models to distributed, home-based, and digitally connected networks. In 2025, the U.S. home care market is projected to generate over $107 billion in revenue, driven by a rapidly aging population, caregiver shortages, and a cultural shift toward aging in place.[9]

This ecosystem includes primary specialists, allied health professionals, community services, caregivers, and digitally connected family members coordinated around the older person. More older adults can meet their daily care needs, as older adults are functioning better on their own and a shrinking share are living in nursing homes and assisted living settings than a decade ago. Home modifications and assistive devices such as walkers have helped older Americans maintain their independence.[6][1]

For life science companies, this distribution of care creates new decision points and influencers. Caregivers and facilities become critical channels, and data flows across settings redefine how value is measured and rewarded. The key to transforming the future of senior care lies in delivering an innovative, integrated experience for both seniors and caregivers. Companies that understand and engage this distributed ecosystem will have an advantage in market access, adherence, and brand trust.[10]

The longevity imperative raises four fundamental strategic questions with the greatest potential for impact on market performance and ROI.

Before deploying resources toward longevity-focused initiatives, leaders must ask the right diagnostic questions to evaluate organizational readiness and identify gaps in current strategy roadmaps.

A phased roadmap can guide life science companies from diagnosis to deployment.

Throughout this roadmap, technology serves as an enabler, not a standalone strategy. The most effective approaches integrate advanced analytics, digital platforms, and AI into strategic decision-making and operational execution, making technology work for business strategy rather than the other way around.[16]

The rise of the longevity economy presents both a challenge and a once-in-a-generation opportunity. Given the world's changing demographics, society stands at an inflection point where the aging paradigm can be transformed from a societal burden to a dynamic opportunity for economic and social growth. Leaders who design for the 100-year life today will own the most resilient, trusted brands tomorrow.[15]

Companies that develop a long-term longevity strategy will be in the best position to influence and shift the existing paradigm. Whether they pursue M&A to gain key know-how, partner with startups and academic institutions, or leverage their own core competencies, these companies will be better able to compete as they help bring about a future of aging and health in which humans live healthier and longer lives than ever before.[2]

The question for life science leaders is not whether these demographic shifts will occur, but whether your organization will be positioned to lead in the longevity era or be disrupted by those who move first.

References